57
Views
4
CrossRef citations to date
0
Altmetric
Commentary

Myeloma antioxidant status: the good, the bad and the reactive

&
Pages 691-693 | Published online: 21 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Duanfeng Jiang, Kaixuan Zhang, Yinghong Zhu, Yan Zhu, Lang Zou, Jian Hu, Yajuan Cui, Wen Zhou, Fangping Chen & Yanjuan He. (2021) Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells. OncoTargets and Therapy 14, pages 4061-4075.
Read now
Yingjie Hong, Jing Yu, Gang Wang & Weisong Qiao. (2019) Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis. Hematology 24:1, pages 216-224.
Read now

Articles from other publishers (2)

Baidarbhi Chakraborty, Gaurav Vishnoi, Srinivas H Gowda & Binita Goswami. (2017) Interleukin-6 gene-174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma. Asia-Pacific Journal of Clinical Oncology 13:5, pages e402-e407.
Crossref
Wafa Hassen, Alboukadel Kassambara, Thierry Reme, Surinder Sahota, Anja Seckinger, Laure Vincent, Guillaume Cartron, Jérôme Moreaux, Dirk Hose & Bernard Klein. (2014) Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget 6:8, pages 6431-6447.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.